Edinburgh Research Explorer

Safety profile of autologous macrophage therapy for liver cirrhosis

Research output: Contribution to journalArticle

  • Catriona Graham
  • Chloe Pass
  • Laura Bailey
  • Lisa Ritchie
  • Donna Mitchell
  • Alison Glover
  • Audrey Laurie
  • Stuart Doig
  • Emily Hargreaves
  • Alasdair R Fraser
  • Marc L Turner
  • John D M Campbell
  • Neil W A McGowan
  • Jacqueline Barry
  • Joanna Moore
  • Diana J Leeming
  • Mette J Nielsen
  • Kishwar Musa

Related Edinburgh Organisations

Original languageEnglish
JournalNature Medicine
DOIs
Publication statusPublished - 7 Oct 2019

Abstract

Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in 9 adults with cirrhosis and Model for End-Stage Liver Disease (MELD) score of 10-16 (ISRCTN10368050). Groups of 3 participants received a single peripheral infusion of 107, 108, or up to 109 cells. Leukapheresis and macrophage infusion was well-tolerated with no transfusion reactions, dose-limiting toxicities or macrophage activation syndrome. All participants were alive and transplant-free at 1 year, with only 1 clinical event recorded, the occurrence of minimal ascites. The primary outcomes of safety and feasibility were met. This study informs and provides a rationale for efficacy studies in cirrhosis and other fibrotic diseases.

ID: 110659044